Market Spotlight: Pancreatic Cancer
Market Spotlight: Pancreatic Cancer
$1,318.00
This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 462,100 incident cases of pancreatic cancer worldwide, and expects that number to increase to 486,300 incident cases by 2028.
- The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, poly ADP-ribose polymerase (PARP), dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor (EGFR). These drugs are commonly administered via the intravenous route, with a few select products being available in oral and intratumoral formulations.
- The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II. Therapies in development for pancreatic cancer focus on a wide variety of targets. The majority of pipeline drugs for pancreatic cancer are administered via the oral or intravenous routes.
- High-impact upcoming events for drugs in the pancreatic cancer space comprise topline Phase I/II trial results for aldoxorubicin; topline Phase II trial results for motixafortide and MesoPher; topline Phase III trial results for pamrevlumab and Onivyde; and an expected patent expiration for Abraxane.
- The overall likelihood of approval of a Phase I pancreatic cancer asset is 1.7%, and the average probability a drug advances from Phase III is 12.5%. Drugs, on average, take 10.7 years from Phase I to approval, compared to 9.7 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for pancreatic cancer have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
- The US has a substantial lead in the number of pancreatic cancer clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the pancreatic cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for pancreatic cancer, with 108 trials.
- Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for pancreatic cancer, followed by Roche.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Surgery
9 Ablation or embolization
10 Radiation therapy
10 Chemotherapy
10 Targeted therapy
11 Immunotherapy
11 Drugs used specifically for the treatment of PNETs
12 EPIDEMIOLOGY
15 MARKETED DRUGS
18 PIPELINE DRUGS
33 RECENT EVENTS AND ANALYST OPINION
33 Anktiva for Pancreatic Cancer (January 18, 2022)
34 CPI-613 for Pancreatic Cancer (October 28, 2021)
36 ERY-ASP for Pancreatic Cancer (October 25, 2021)
38 Relacorilant for Pancreatic Cancer (June 22, 2021)
39 GV1001 for Pancreatic Cancer (June 6, 2021)
40 Motixafortide for Pancreatic Cancer (December 16, 2020)
42 Masitinib for Pancreatic Cancer (December 4, 2020)
45 KEY UPCOMING EVENTS
46 PROBABILITY OF SUCCESS
47 LICENSING AND ASSET ACQUISITION DEALS
47 Synthetic Biologics To Acquire Immunotherapy Firm VCN
47 Gilead Opts In On Multiple Arcus IO Candidates, Setting Up Combo Therapy Plans
47 China CSPC Subsidiary Out-Licenses Oncology Candidate To Flame Biosciences
48 Chinese Cell Developers To Jointly Develop Solid Tumor Therapies
48 Processa Licenses Global Rights For RX-3117 From Ocuphire
48 Laevoroc Oncology Acquires Worldwide Patents For LR06
48 Lantern Pharma Enters Research And Development Collaboration with Actuate Therapeutics
48 CytoImmune Acquires City Of Hope Cell Therapy IP
49 University of Texas MD Anderson Cancer Center Unveils Collaboration With TriSalus Life Sciences
49 MD Anderson Inks New Cancer Collaboration With Mirati, Orionis
49 Qilu Obtains Greater China Rights To Cend’s Cancer Candidate
51 REVENUE OPPORTUNITY
54 CLINICAL TRIAL LANDSCAPE
55 Sponsors by status
56 Sponsors by phase
57 Recent events
61 BIBLIOGRAPHY
62 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of pancreatic cancer, 2019–28
18 Figure 2: Overview of pipeline drugs for pancreatic cancer in the US
18 Figure 3: Pipeline drugs for pancreatic cancer, by company
19 Figure 4: Pipeline drugs for pancreatic cancer, by drug type
19 Figure 5: Pipeline drugs for pancreatic cancer, by classification
34 Figure 6: Anktiva for Pancreatic Cancer (January 18, 2022): Phase II – QUILT-88
36 Figure 7: CPI-613 for Pancreatic Cancer (October 28, 2021): Phase III – AVENGER 500 (w/mFolfirinox)
39 Figure 8: Relacorilant for Pancreatic Cancer (June 22, 2021): Phase III – RELIANT (w/Nab-Paclitaxel)
42 Figure 9: Motixafortide for Pancreatic Cancer (December 16, 2020): Phase IIa – COMBAT/KEYNOTE-202 (w/Keytruda)
44 Figure 10: Masitinib for Pancreatic Cancer (December 4, 2020): Phase III – AB12005
55 Figure 11: Key upcoming events in pancreatic cancer
46 Figure 12: Probability of success in the pancreatic cancer pipeline
54 Figure 13: Clinical trials in pancreatic cancer
54 Figure 14: Top 10 drugs for clinical trials in pancreatic cancer
55 Figure 15: Top 10 companies for clinical trials in pancreatic cancer
55 Figure 16: Trial locations in pancreatic cancer
56 Figure 17: Pancreatic cancer trials status
57 Figure 18: Pancreatic cancer trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of pancreatic cancer, 2019–28
16 Table 2: Marketed drugs for pancreatic cancer
20 Table 3: Pipeline drugs for pancreatic cancer in the US
33 Table 4: Anktiva for Pancreatic Cancer (January 18, 2022)
35 Table 5: CPI-613 for Pancreatic Cancer (October 28, 2021)
37 Table 6: ERY-ASP for Pancreatic Cancer (October 25, 2021)
38 Table 7: Relacorilant for Pancreatic Cancer (June 22, 2021)
40 Table 8: GV1001 for Pancreatic Cancer (June 6, 2021)
41 Table 9: Motixafortide for Pancreatic Cancer (December 16, 2020)
43 Table 10: Masitinib for Pancreatic Cancer (December 4, 2020)
52 Table 11: Historical global sales, by drug ($m), 2016–20
53 Table 12: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Cachexia 
Sign up to the